Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention NHS England, the most common co-covered peer. Each carries 9 original sources on average. We currently track 1 Biotech story that mention Puberty Blockers, all published on February 20, 2026.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention NHS England, the most common co-covered peer. Each carries 9 original sources on average. We currently track 1 Biotech story that mention Puberty Blockers, all published on February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Puberty Blockers. Shared-story counts are live from our verified record — not editorial picks.
MHRA Intervention
The UK medicines regulator issues a formal pause on the trial due to newly identified concerns.
Clinical Trial Launch
NHS England begins the formal clinical trial to gather data on the effects of puberty blockers.
Cass Review Published
Final report recommends that puberty blockers only be administered within a research framework.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has suspended a pivotal clinical trial investigating the use of puberty blockers for children. The pause follows the emergence of new regulatory concerns, effectively halting the primary research pathway for gender-affirming care in the UK.
Puberty Blockers is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
